AtriCure (ATRC) Q2 2026 earnings review
Profitability Accelerates Despite Slight Revenue Deceleration
AtriCure delivered a standout quarter characterized by massive margin expansion. While top-line growth decelerated slightly to 12.8% YoY (down from 14.3% in Q1), the volume flow-through to the bottom line was exceptional. Adjusted EBITDA accelerated 78% YoY to $27.3M, and GAAP net income reversed from a loss into positive territory ($9.0M). Management raised full-year FY26 guidance for both revenue and EBITDA, reflecting strong momentum in the Pain Management and Appendage Management franchises, which continue to offset the structural collapse in the Minimally Invasive Ablation business.
🐂 Bull Case
Gross margin expanded 269 basis points to 77.2%, driving a 78% surge in Adjusted EBITDA. The company has proven it can scale its top-line while maintaining expense discipline, achieving a record level of profitability.
The US Pain Management segment continues to be a growth engine, expanding nearly 28% YoY, supported by rapid adoption of the cryoSPHERE MAX probe. Appendage management also remains strong, growing double-digits in the US.
🐻 Bear Case
The US Minimally Invasive Ablation segment plummeted 23% YoY. It has fallen victim to intensifying competition from PFA catheter technologies, with no immediate floor in sight.
International revenue grew just 7.1% on a constant currency basis, a stark deceleration from the ~20% rates seen in FY25. Macro-level funding issues, particularly with the UK's NHS, continue to weigh on overseas performance.
⚖️ Verdict: 🟢
Bullish. The 23% drop in the MIS business is a known headwind, but the company's ability to drive 12.8% overall growth while expanding gross margins by 269 bps and nearly doubling EBITDA highlights the sheer strength of its broader product portfolio.
Key Themes
Pain Management Franchise Powers U.S. Outperformance
U.S. Pain Management remains AtriCure's fastest-growing segment, accelerating 27.8% YoY to $27.1 million. The innovation cycle—specifically the transition to the cryoSPHERE MAX probe, which drastically reduces procedure times—has cemented this segment as a durable driver. This segment alone accounted for over 40% of the absolute dollar growth in the U.S. market this quarter.
Gross Margin Reaches Exceptional Levels
Gross margin reversed its historical trend of remaining static in the ~74.5% to ~75.5% range, jumping 269 basis points YoY to 77.2%. Management attributed this to favorable product and geographic mix, alongside manufacturing efficiencies. This margin profile is what unlocked the massive leap in Adjusted EBITDA.
Minimally Invasive Ablation Continues Freefall
The narrative that the Minimally Invasive (MIS) business is under severe pressure was firmly corroborated by Q2 data. U.S. MIS ablation revenue decelerated rapidly, plunging 23.1% YoY to $6.0 million. Electrophysiologists are actively adopting competing PFA catheter solutions, heavily cannibalizing AtriCure's Hybrid AF therapy pipeline. This directly contradicts the bullish narrative of an untouchable competitive moat across the company's entire portfolio.
Clinical Evidence Driving Market Expansion
Long-term growth is tethered to major clinical milestones, specifically the LeAAPS and BoxX-NoAF trials. By driving robust, product-specific evidence, AtriCure aims to establish prophylactic appendage exclusion and ablation as standard-of-care. Management reiterated that these readouts are critical to unlocking the next multi-billion-dollar wave of cardiac surgery adoption.
Macro Pressures Stifle International Growth
International constant-currency revenue growth was stable but severely muted at 7.1%, yielding $28.0 million. This marks a massive deceleration from the ~20% constant currency growth reported in Q2 of FY25. Previous management commentary flagged macro headwinds, specifically funding and reimbursement uncertainty within the U.K. National Health Service, which appears to be creating an ongoing drag on the overseas business.
New Manufacturing Facilities May Dilute Margins
While current gross margins are spectacular at 77.2%, management warned in the prior quarter that new manufacturing facilities coming online in the second half of 2026 would introduce increased cost burdens. Investors should be cautious not to extrapolate this quarter's record margin into Q3 and Q4 without adjusting for these incoming overhead expenses.
Other KPIs
Accelerating from previous quarters. Cash generation remains robust, padding the balance sheet to $167.8M in cash and equivalents. This limits any near-term dilution risk and provides a war chest for further pipeline innovation.
Stable double-digit growth of +14.4% YoY. Despite known incoming competition from major med-tech players (Medtronic, Edwards), the AtriClip franchise is holding its dominant market position, driven by conversions to the FLEX-Mini and PRO-Mini devices.
Guidance
Stable. Raised the bottom end of the range from $600M. The $606M midpoint implies approximately 13.4% YoY growth from FY25's $534.5M, suggesting H2 will perform roughly in-line with the 13-14% growth experienced in H1.
Accelerating. Materially raised from the previous guidance of $80 - $82 million. The new $87M midpoint represents roughly a 40% jump compared to FY25's $61.8M, showcasing profound operating leverage unlocking heading into the back half of the year.
Reversing. Significantly raised from previous ranges, pointing to definitive, sustainable profitability on an adjusted basis, compared to FY25's adjusted loss of $0.11 per share.
Key Questions
Minimally Invasive Ablation Bottom
With the U.S. MIS business down another 23% this quarter, what is the internal forecast for when this segment will find a structural floor against PFA catheter competition?
Gross Margin Sustainability
Gross margin reached a stellar 77.2%. How much of the 269 bps YoY expansion was driven by structural manufacturing efficiencies versus transient favorable product/geographic mix? And how will new facility costs in H2 specifically impact this rate?
International Macro Headwinds
International constant-currency growth decelerated to 7.1%. To what extent is this deceleration tied strictly to the NHS funding issues in the U.K. versus competitive or adoption roadblocks in other key markets like Europe or Asia?